Clinical Trials Logo

Non-small Cell Lung Cancer NSCLC clinical trials

View clinical trials related to Non-small Cell Lung Cancer NSCLC.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06454890 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer NSCLC

Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

Start date: August 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-Trop2 U-CAR-NK Cells Therapy combined with Chemotherapy for Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC).

NCT ID: NCT06416852 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer NSCLC

Clinical Study of 18F-Alfatide Injection PET/CT

Start date: August 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter, open, non-inferiority Phase III clinical study to evaluate the efficacy of 18F-Alfatide Injection PET/CT compared with 18F-FDG PET/CT in the diagnosis of lymph node metastasis in non-small cell lung cancer. This trial will include 428 patients with non-small cell lung cancer confirmed by imaging, histopathology and/or cytology or highly suspected by investigators, suspected lymph node metastasis and proposed radical surgery and lymph node dissection. Eligible subjects will receive 18F-Alfatide Injection PET/CT and 18F-FDG PET/CT scans within 1 week. Subjects will undergo relevant security checks before and after each scan. The subjects underwent radical surgery and lymph node dissection within 2 weeks of completing both scans, and the obtained lymph nodes were pathologically examined as the gold standard to compare the diagnostic efficacy of 18F-Alfatide versus 18F-FDG for lymph node metastasis.